Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent with the ability to induce cell death selectively in cancer cells while spare the normal cells. However, the application of TRAIL-based anti-tumor therapies has been hampered by the resistance. Alternol, a novel compound which can be purified from microbial fermentation, possess anti-tumor activity in various cancers.
INTRODUCTION AND OBJECTIVES:
Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent with the ability to induce cell death selectively in cancer cells while spare the normal cells. However, the application of TRAIL-based anti-tumor therapies has been hampered by the resistance. Alternol, a novel compound which can be purified from microbial fermentation, possess anti-tumor activity in various cancers.
METHODS: siRNA were synthesized to against the expression of DR4, DR5 and CHOP. MTT assay was used to measure cytotoxic activity of alternol and TRAIL or in combination on RCC cells. The apoptotic rate was measured by using Annexin V/PI assay. Changes of protein and mRNA were investigated by Western Blot and realtimePCR. Luciferase assay analyzed whether CHOP transcriptionally controlled the alternol-induced up-regulation of DR5 expression. Tumour xenograft model tested anti-tumor effects of alternol/TRAIL in vivo.
RESULTS: In this study, we found alternol was able to sensitize TRAIL resistant renal carcinoma cells to TRAIL-induced apoptosis. When investigated for the mechanisms, we found that alternol induced the up-regulation of death receptor (DR)5. Silencing of DR5 by RNA interference abrogated the sensitizing effect of alternol on TRAILmediated apoptosis. Moreover, alternol decreased the expression of anti-apoptotic proteins while increased the expression of pro-apoptotic proteins. In addition, alternol up-regulates the expression of CHOP which is required for the sensitizing effect of alternol on TRAIL-induced apoptosis since silencing of CHOP abolished the synergistic effect. We also observed that alternol-induced up-regulation of DR5 was dependent on the production of reactive oxygen species (ROS). Remove of ROS abolished the induction of DR5 and suppression of anti-apoptotic proteins by alternol.
CONCLUSIONS: Our results indicate that alternol potentiates TRAIL-mediated apoptosis through inhibition of anti-apoptotic proteins and up-regulation of DR5 through the generation of ROS and CHOP pathway.
Source of Funding: none

MP72-09 RITONAVIR AND IXAZOMIB INHIBIT RENAL CANCER GROWTH IN VITRO AND IN VIVO BY INDUCING ENDOPLASMIC RETICULUM STRESS SYNERGISTICALLY
Takako Asano*, Akinori Sato, Kazuki Okubo, Makoto Isono, Tomohiko Asano, Tokorozawa, Japan INTRODUCTION AND OBJECTIVES: Inducing endoplasmic reticulum (ER) stress is a novel strategy for treating cancer. The human immunodeficiency virus protease inhibitor ritonavir suppresses heat shock protein 90 and increases unfolded proteins in the cell. We postulated that combining it with the novel proteasome inhibitor ixazomib would kill cancer cells effectively by inhibiting the degradation of these unfolded proteins and thereby inducing ER stress.
METHODS: Renal cancer cells (769-P, 786-O, ACHN, Caki-1, Caki-2) were treated with ritonavir (20-40 mM) and/or ixazomib (50-200 nM). Cell viability and clonogenicity were assessed by MTS assay and colony formation assay. In vivo efficacy was evaluated using murine subcutaneous tumor models. Apoptosis was evaluated by annexin-V assay. Cell cycle analysis was done using flow cytometry. Western blotting was used to evaluate the induction of ER stress and the expression of apoptosis-associated proteins, cell cycle-associated proteins, NOXA, acetylated histone, and histone deacetylases (HDACs).
RESULTS: The combination of ritonavir and ixazomib induced drastic apoptosis (up to 93.4% annexin V-positive cells) and inhibited renal cancer growth synergistically (combination indexes < 1). It also suppressed colony formation significantly (p < 0.05). The combination decreased the expression of cyclin D1 and cyclin-dependent kinase 4, leading to the accumulation of the cells in the sub-G1 fraction. In murine subcutaneous tumor models using Caki-2 cells, a 10-day treatment with 50 mg/kg ritonavir and 0.6 mg/kg ixazomib was well tolerated and inhibited tumor growth significantly (p < 0.05). Mechanistically, the combination synergistically induced ER stress evidenced by the increased expression of the ER stress markers glucose-regulated protein 78, endoplasmic reticulum resident protein 44, and endoplasmic oxidoreductin-1-like protein. Furthermore, increased expression of NOXA confirmed that the combination-induced apoptosis was a result of ER stress. Interestingly, we also found that the combination induced histone acetylation synergistically by decreasing the expression of HDAC1, 3 and 6.
CONCLUSIONS: Ritonavir combined with ixazomib inhibits the growth of renal cancer cells by synergistically inducing ER stress. Histone acetylation is also an important mechanism of the combination's action.
Source of Funding: none
MP72-10 PHARMACOGENETIC-BASED AUC MODEL CAN PREDICT EFFICACY AND ADVERSE EVENTS OF AXITINIB IN INDIVIDUAL PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
Yoshiaki Yamamoto*, Ryouichi Tsunedomi, Yusuke Fujita, Ube, Japan; Toru Otori, Higashiosaka, Japan; Yoshihisa Kawai, Ryo Inoue, Hiroshi Hirata, Hiroaki Matsumoto, Tomoyuki Shimabukuro, Ube, Japan; Rajvir Dahiya, San Francisco, CA; Hideyasu Matsuyama, Ube, Japan INTRODUCTION AND OBJECTIVES: Although titrated-dose axitinib offers a good objective response rate (ORR) for metastatic renal cell carcinoma (RCC), its optimal initial dose is unclear because its dosing regimen is mainly based on a hypertensive reaction. We investigated whether axitinib pharmacogenetics were related to clinical efficacy/adverse events (AEs), and calculated a model to predict clinical efficacy and AEs, using pharmacokinetic data based on gene polymorphisms related to drug metabolism and efflux.
METHODS: We prospectively evaluated ORR and AEs in 44 consecutive advanced RCC patients treated with axitinib between Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 THE JOURNAL OF UROLOGY â e955
